Sydney Adventist Hospital 02 9487 9111


Sydney Adventist Hospital
« View pages

Clinical Specialties

Prostate Cancer Clinical Trials

Cougar 302

A phase 3, randomised, double-blind, placebo-controlled study of Abiraterone Acetate (CB7630) plus Prednisone in Asymptomatic Castration-Resistant Prostate Cancer

http://clinicaltrials.gov/ct2/show/NCT00887198


Prevail

Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Metastatic Prostate Cancer Who Have Failed on Androgen Deprivation Therapy and Have Not Received Previous Chemotherapy

http://clinicaltrials.gov/ct2/show/NCT01212991


Mic-1 - Recruiting

Phase II Study to Investigate the Ability of Macrophage Inhibitory Cytokine-1 (MIC-1)

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335301


Plato

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

http://clinicaltrials.gov/ct2/show/NCT01995513


Prosper - Recruiting

A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.

http://clinicaltrials.gov/ct2/show/NCT02003924


Prospect 

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer

http://clinicaltrials.gov/ct2/show/NCT01322490


Enzamet – Recruiting

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365575


Enzarad – Recruiting

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365611


Spartan

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (SPARTAN)

http://clinicaltrials.gov/ct2/show/NCT01946204?term=spartan&rank=4


ACIS

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

https://www.clinicaltrials.gov/ct2/show/NCT02257736?term=PCR3001&rank=2


Embark – Recruiting

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With HighRisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

https://www.clinicaltrials.gov/ct2/show/NCT02319837?term=Safety+and+Efficacy+Study+of+Enzalutamide&rank=3


Keynote 199  

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199

https://clinicaltrials.gov/ct2/show/NCT02787005?term=Keynote+199&rank=1

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services